The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers

Elizabeth K. Bancroft; Elizabeth C. Page; Mark N. Brook; Jennifer Pope; Sarah Thomas; Kathryn Myhill; Brian T. Helfand; Pooja Talaty; Kai Ren Ong; Emma Douglas; Jackie Cook; Derek J. Rosario; Monica Salinas; Saundra S. Buys; Jo Anson; Rosemarie Davidson; Mark Longmuir; Lucy Side; Diana M. Eccles; Marc Tischkowitz; Amy Taylor; Mara Cruellas; Eduard Perez Ballestero; Ruth Cleaver; Mohini Varughese; Julian Barwell; Mandy LeButt; Lynn Greenhalgh; Rachel Hart; Ashraf Azzabi; Irene Jobson; Lynn Cogley; D. Gareth Evans; Jeanette Rothwell; Natalie Taylor; Matthew Hogben; Sibel Saya; Margreet G.E.M. Ausems; Rob B. Van der Luijt; M. T.W.T. Lock

doi:10.1111/bju.16432

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers

Elizabeth K. Bancroft^*, Elizabeth C. Page, Mark N. Brook, Jennifer Pope, Sarah Thomas, Kathryn Myhill, Brian T. Helfand, Pooja Talaty, Kai Ren Ong, Emma Douglas, Jackie Cook, Derek J. Rosario, Monica Salinas, Saundra S. Buys, Jo Anson, Rosemarie Davidson, Mark Longmuir, Lucy Side, Diana M. Eccles, Marc TischkowitzAmy Taylor, Mara Cruellas, Eduard Perez Ballestero, Ruth Cleaver, Mohini Varughese, Julian Barwell, Mandy LeButt, Lynn Greenhalgh, Rachel Hart, Ashraf Azzabi, Irene Jobson, Lynn Cogley, D. Gareth Evans, Jeanette Rothwell, Natalie Taylor, Matthew Hogben, Sibel Saya, Margreet G.E.M. Ausems, Rob B. Van der Luijt, M. T.W.T. Lock,

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Objectives: To report the long-term outcomes from a longitudinal psychosocial study that forms part of the ‘Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls’ (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2). Subjects and Methods: Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge. Results: A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P < 0.001). Cancer risk perceptions reflected information provided during genetic counselling and participants had good levels of knowledge, although this declined over time. Conclusion: This is the first study to report the longitudinal psychosocial impact of a targeted PrCa screening programme for BRCA1 and BRCA2 carriers. The results reassure that an annual PSA-based screening programme does not have an adverse impact on psychosocial health or health-related quality of life in these higher-risk individuals. These results are important as more PrCa screening is targeted to higher-risk groups.

Original language	English
Pages (from-to)	484-500
Number of pages	17
Journal	BJU International
Volume	134
Issue number	3
DOIs	https://doi.org/10.1111/bju.16432
Publication status	Published - Sept 2024

Keywords

BRCA1
BRCA2
genetic screening
prostate cancer
psychosocial
quality of life

Access to Document

10.1111/bju.16432Licence: CC BY

BJU International - 2024 - Bancroft - The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriersFinal published version, 548 KBLicence: CC BY

Cite this

Bancroft, E. K., Page, E. C., Brook, M. N., Pope, J., Thomas, S., Myhill, K., Helfand, B. T., Talaty, P., Ong, K. R., Douglas, E., Cook, J., Rosario, D. J., Salinas, M., Buys, S. S., Anson, J., Davidson, R., Longmuir, M., Side, L., Eccles, D. M. (2024). The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers. BJU International, 134(3), 484-500. https://doi.org/10.1111/bju.16432

@article{605d3a17eac84037b74d28539be6a278,

title = "The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers",

abstract = "Objectives: To report the long-term outcomes from a longitudinal psychosocial study that forms part of the {\textquoteleft}Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls{\textquoteright} (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2). Subjects and Methods: Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge. Results: A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P < 0.001). Cancer risk perceptions reflected information provided during genetic counselling and participants had good levels of knowledge, although this declined over time. Conclusion: This is the first study to report the longitudinal psychosocial impact of a targeted PrCa screening programme for BRCA1 and BRCA2 carriers. The results reassure that an annual PSA-based screening programme does not have an adverse impact on psychosocial health or health-related quality of life in these higher-risk individuals. These results are important as more PrCa screening is targeted to higher-risk groups.",

keywords = "BRCA1, BRCA2, genetic screening, prostate cancer, psychosocial, quality of life",

author = "Bancroft, {Elizabeth K.} and Page, {Elizabeth C.} and Brook, {Mark N.} and Jennifer Pope and Sarah Thomas and Kathryn Myhill and Helfand, {Brian T.} and Pooja Talaty and Ong, {Kai Ren} and Emma Douglas and Jackie Cook and Rosario, {Derek J.} and Monica Salinas and Buys, {Saundra S.} and Jo Anson and Rosemarie Davidson and Mark Longmuir and Lucy Side and Eccles, {Diana M.} and Marc Tischkowitz and Amy Taylor and Mara Cruellas and Ballestero, {Eduard Perez} and Ruth Cleaver and Mohini Varughese and Julian Barwell and Mandy LeButt and Lynn Greenhalgh and Rachel Hart and Ashraf Azzabi and Irene Jobson and Lynn Cogley and Evans, {D. Gareth} and Jeanette Rothwell and Natalie Taylor and Matthew Hogben and Sibel Saya and Zsofia Kote-Jarai and Audrey Ardern-Jones and Chris Bangma and Ausems, {Margreet G.E.M.} and {Van der Luijt}, {Rob B.} and Dijkman, {G. A.} and Jong, {I. J.} and Lock, {M. T.W.T.} and Schaaf, {M. J.} and Smits, {G. A.H.J.} and S. Smorenburg and {van der Poel}, {H. G.} and Verhulst, {A. P.M.}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International.",

year = "2024",

month = sep,

doi = "10.1111/bju.16432",

language = "English",

volume = "134",

pages = "484--500",

journal = "BJU International",

issn = "1464-4096",

publisher = "Wiley-Blackwell",

number = "3",

}

Bancroft, EK, Page, EC, Brook, MN, Pope, J, Thomas, S, Myhill, K, Helfand, BT, Talaty, P, Ong, KR, Douglas, E, Cook, J, Rosario, DJ, Salinas, M, Buys, SS, Anson, J, Davidson, R, Longmuir, M, Side, L, Eccles, DM, Tischkowitz, M, Taylor, A, Cruellas, M, Ballestero, EP, Cleaver, R, Varughese, M, Barwell, J, LeButt, M, Greenhalgh, L, Hart, R, Azzabi, A, Jobson, I, Cogley, L, Evans, DG, Rothwell, J, Taylor, N, Hogben, M, Saya, S, Ausems, MGEM, Van der Luijt, RB, Lock, MTWT 2024, 'The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers', BJU International, vol. 134, no. 3, pp. 484-500. https://doi.org/10.1111/bju.16432

TY - JOUR

T1 - The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers

AU - Bancroft, Elizabeth K.

AU - Page, Elizabeth C.

AU - Brook, Mark N.

AU - Pope, Jennifer

AU - Thomas, Sarah

AU - Myhill, Kathryn

AU - Helfand, Brian T.

AU - Talaty, Pooja

AU - Ong, Kai Ren

AU - Douglas, Emma

AU - Cook, Jackie

AU - Rosario, Derek J.

AU - Salinas, Monica

AU - Buys, Saundra S.

AU - Anson, Jo

AU - Davidson, Rosemarie

AU - Longmuir, Mark

AU - Side, Lucy

AU - Eccles, Diana M.

AU - Tischkowitz, Marc

AU - Taylor, Amy

AU - Cruellas, Mara

AU - Ballestero, Eduard Perez

AU - Cleaver, Ruth

AU - Varughese, Mohini

AU - Barwell, Julian

AU - LeButt, Mandy

AU - Greenhalgh, Lynn

AU - Hart, Rachel

AU - Azzabi, Ashraf

AU - Jobson, Irene

AU - Cogley, Lynn

AU - Evans, D. Gareth

AU - Rothwell, Jeanette

AU - Taylor, Natalie

AU - Hogben, Matthew

AU - Saya, Sibel

AU - Kote-Jarai, Zsofia

AU - Ardern-Jones, Audrey

AU - Bangma, Chris

AU - Ausems, Margreet G.E.M.

AU - Van der Luijt, Rob B.

AU - Dijkman, G. A.

AU - Jong, I. J.

AU - Lock, M. T.W.T.

AU - Schaaf, M. J.

AU - Smits, G. A.H.J.

AU - Smorenburg, S.

AU - van der Poel, H. G.

AU - Verhulst, A. P.M.

PY - 2024/9

Y1 - 2024/9

N2 - Objectives: To report the long-term outcomes from a longitudinal psychosocial study that forms part of the ‘Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls’ (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2). Subjects and Methods: Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge. Results: A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P < 0.001). Cancer risk perceptions reflected information provided during genetic counselling and participants had good levels of knowledge, although this declined over time. Conclusion: This is the first study to report the longitudinal psychosocial impact of a targeted PrCa screening programme for BRCA1 and BRCA2 carriers. The results reassure that an annual PSA-based screening programme does not have an adverse impact on psychosocial health or health-related quality of life in these higher-risk individuals. These results are important as more PrCa screening is targeted to higher-risk groups.

AB - Objectives: To report the long-term outcomes from a longitudinal psychosocial study that forms part of the ‘Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls’ (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2). Subjects and Methods: Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge. Results: A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P < 0.001). Cancer risk perceptions reflected information provided during genetic counselling and participants had good levels of knowledge, although this declined over time. Conclusion: This is the first study to report the longitudinal psychosocial impact of a targeted PrCa screening programme for BRCA1 and BRCA2 carriers. The results reassure that an annual PSA-based screening programme does not have an adverse impact on psychosocial health or health-related quality of life in these higher-risk individuals. These results are important as more PrCa screening is targeted to higher-risk groups.

KW - BRCA1

KW - BRCA2

KW - genetic screening

KW - prostate cancer

KW - psychosocial

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=85199880453&partnerID=8YFLogxK

U2 - 10.1111/bju.16432

DO - 10.1111/bju.16432

M3 - Article

AN - SCOPUS:85199880453

SN - 1464-4096

VL - 134

SP - 484

EP - 500

JO - BJU International

JF - BJU International

IS - 3

ER -

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this